PDF(Pubmed)
Abstract：
Fusobacterium nucleatum, an anaerobic Gram-negative bacterium primarily residing in the oral cavity, has garnered significant attention for its emerging role in cancer progression and prognosis. While extensive research has revealed mechanistic links between Fusobacterium nucleatum and colorectal cancer, a comprehensive review spanning its presence and metastatic implications in cancers beyond colorectal origin is conspicuously absent. This paper broadens our perspective from colorectal cancer to various malignancies associated with Fusobacterium nucleatum, including oral, pancreatic, esophageal, breast, and gastric cancers. Our central focus is to unravel the mechanisms governing Fusobacterium nucleatum colonization, initiation, and promotion of metastasis across diverse cancer types. Additionally, we explore Fusobacterium nucleatum\'s adverse impacts on cancer therapies, particularly within the domains of immunotherapy and chemotherapy. Furthermore, this paper underscores the clinical research significance of Fusobacterium nucleatum as a potential tumor biomarker and therapeutic target, offering a novel outlook on its applicability in cancer detection and prognostic assessment.
摘要：
具核梭杆菌,一种主要存在于口腔中的厌氧革兰氏阴性细菌，因其在癌症进展和预后中的新兴作用而受到关注。虽然广泛的研究揭示了核梭杆菌和结直肠癌之间的机械联系，关于其在结直肠癌以外的癌症中的存在和转移影响的全面审查显然缺乏。本文将我们的观点从结直肠癌扩展到与核梭杆菌相关的各种恶性肿瘤，包括口服,胰腺,食道,乳房,和胃癌。我们的中心重点是解开管核梭杆菌定植的机制，initiation,以及促进不同癌症类型的转移。此外,我们探讨了核梭杆菌对癌症治疗的不利影响，特别是在免疫治疗和化疗领域。此外，本文强调核梭杆菌作为一种潜在的肿瘤生物标志物和治疗靶点的临床研究意义,对其在癌症检测和预后评估中的适用性提出了新的展望。
